Treatment of acute diarrhea with Saccharomyces boulardii in infants.

OBJECTIVE: The aim of the study was to determine whether an oral treatment with a commercial pharmaceutical product containing Saccharomyces boulardii would reduce the duration of diarrhea in infants with acute diarrhea. PATIENTS AND METHODS: In the present double-blind, placebo-controlled study, 186 infants, 6 to 48 months old and hospitalized within 72 hours after the onset of acute diarrhea in 2 hospitals in Goiânia, Goiás, Brazil, were randomly assigned to receive twice per day for 5 days 200 mg of a commercial pharmaceutical product containing 4 × 10 viable cells of S boulardii or a placebo. Stool samples were submitted to search for rotavirus. Among the 176 infants who completed the trial, those treated with S boulardii (90) showed a reduction in diarrhea duration (P < 0.05) when compared with the placebo group (86). RESULTS: The present study shows a reduction in diarrhea duration when S boulardii was given to children within 72 hours after the onset of acute diarrhea. CONCLUSIONS: The present study suggests a complementary treatment of acute diarrhea in infants with daily oral doses of S boulardii.

A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants.

GOALS: This clinical trial was carried out to determine whether oral treatment with a commercial probiotic formula containing Bifidobacterium lactis and Streptococcus thermophilus would reduce the frequency of antibiotic-associated diarrhea (AAD) in infants. STUDY: In this double-bind formula controlled study, 80 infants, 6 to 36 months of age, were randomly assigned to receive a commercial formula containing 10 viable cells of B. lactis and 10 viable cells of S. thermophilus at the initiation of antibiotics for a duration of 15 days. The infants were assessed daily for formula intake, stool frequency, and stool consistency for a total duration of 30 days. Seventy-seven infants received nonsupplemented formula for the entire duration. RESULTS: There was a significant difference in the incidence of AAD in the children receiving probiotic-supplemented formula (16%) than nonsupplemented formula (31%). CONCLUSIONS: The present study shows that prevention against AAD in infants was obtained by oral treatment with daily dose of B. lactis and S. thermophilus.

Larva migrans visceral: relato de três casos / Visceral larva migrans: report of 3 cases

Säo relatados três casos de crianças com larva migrans visceral confirmados através do teste imunoenzimático ELISA, en Goiânia. Qaudro pulmonar com infiltrado intersticial, tosse seca e eosinofilia sangüínea caracterizaram o primeiro caso. No segundo, os sinais clínicos presentes foram quadro respiratório com tosse seca, infiltrado pulmonar, além de eosinofilia sangüínea e hipergamaglobulinemia. Uma eosinofilia persistente, entre 1987-1989, sem qualquer outro sinal aparente, foi o que induziu à suspeita e confirmacäo, da parasitose no terceiro caso

Intolerância as proteínas heterológas da dieta: enteropatia as proteínas do leite de vaca, soja e frango e suas manifestaçöes clínicas

As manifestaçöes clínicas de enteropatia induzida pelas proteínas heterólogas da dieta podem ser varáveis dependendo da reaçäo imunológica. Neste trabalho foram estudadas 55 crianças com intolerância alimentar. A idade média dos pacientes foi de 3,9 meses e as manifestaçöes clínicas foram divididas em 2 grupos principais: Síndrome de má absorçäo e colite. Síndrome de má absorçäo foi observado em 40 (72,7%) dos pacientes, enteropatia sensível ao leite de vaca em 24, ao leite de vaca e soja em 16, e leite de vaca, soja e frango em 10 pacientes foram os tipos de intolerância caracterizados